Maravela|Asociații assisted Precision for Medicine, part of Precision Medicine Group, in connection with the Romanian law aspects of its multimillion EUR value cross-border acquisition of Argint International.
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patients more precisely and effectively. With more than 1,450 employees in 25 locations in the US, Canada, and Europe, Precision Medicine Group activates in fields from advanced lab sciences to translational informatics and clinical trial delivery.
Argint International is a contract research organization based in Budapest, Hungary, and it is currently managing studies across 25 countries and more than 600 investigational sites, including several large phase III programs, each involving between 50 and 130 sites. Argint International has a strong presence in Hungary, Poland, Romania, Slovakia and Serbia.
On this transaction, Maravela|Asociații worked closely with the international law firm Bird & Bird, whose London office team coordinated the entire transaction. Maravela|Asociații assisted with all the Romanian jurisdiction related aspects, including due diligence, drafting and negotiating the transaction documents, employment matters, as well as several post completion aspects.
„With another high-valued complex cross border transaction completed, we are glad to further consolidate our niche healthcare M&A position on the market. We are proud to have been selected by Bird & Bird as Romanian counsels and happy to have been part of this significant acquisition.” Dana Rădulescu, Partner of Maravela|Asociații
Partner Dana Rădulescu coordinated the team involved in the acquisition of Argint International, assisted by Senior Associate Daniel Alexie, Senior Associate Irina Radu and Associate Magda Grigore. Employment aspects were coordinated by Partner Alexandra Rîmbu.